LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Hemostasis Analyzers Market Driven by Increasing Awareness of Blood Disorder Conditions

By LabMedica International staff writers
Posted on 09 Feb 2023
Image: The global hemostasis analyzers market is expected to reach close to USD 6 billion in 2026 (Photo courtesy of Pexels)
Image: The global hemostasis analyzers market is expected to reach close to USD 6 billion in 2026 (Photo courtesy of Pexels)

Hemostasis analyzers are devices used for measuring clotting mechanisms of hemostasis in order to detect clotting deficiencies. The body’s natural ability to quickly stop bleeding in order to stop serious blood loss is known as hemostasis. Hemostasis analyzers are used to perform tests such as APTT tests, D dimer tests, platelet function tests, fibrinogen tests, prothrombin time tests, and other tests using optical technology, mechanical technology, electrochemical technology, and other technologies. Within hemostasis analyzers, the main products are clinical laboratory analyzers, point-of-care testing analyzers, and consumables. Clinical laboratory analyzers are used to calculate the concentration of certain substances in various samples. The various end users of hemostasis analyzers are hospitals and clinics, diagnostic centers, research and development organizations and ambulatory surgical centers, among others.

The global hemostasis analyzers market is expected to reach USD 5.97 billion in 2026, driven by the increasing awareness of blood disorder conditions such as Hemophilia and Von Willebrand disease (vWD) which are genetic disorders and not well known to people. This results in late diagnosis of blood disorders and affects patient outcomes. The increasing awareness is expected to improve the diagnosis rate of blood disorders, thereby driving the demand for hemostasis analyzers. However, recalls of defective devices could act as a restraint to the growth of the hemostasis analyzers market. These are the latest findings of ReportLinker (Lyon, France), a market research solution provider.

The hemostasis analyzers market consists of sales of complete blood count (CBC), factor v assay, fibrinogen level, prothrombin time (PT or PT-INR), platelet count, and thrombin time. Manufacturers of hemostasis analyzers are developing portable, handheld hemostasis analyzers which are convenient for carrying anywhere and are small enough to fit in a person's palm. These portable hemostasis analyzers offer a quicker and easier testing process, and facilitate independent analysis of results. Geographically, North America dominated the global hemostasis analyzers market in 2022 with the largest share, followed by Western Europe with the second-largest share.

Related Links:
ReportLinker 

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more